The role of vitamin D in cancer prevention

Chinese Journal of Natural Medicines

Volumn 13, Issue 7, 2015, Pages 481-497

  Ness, Rachel A ^a   Miller, Duane D ^a   Li, Wei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Calcitriol; Cancer prevention; Cancer prognosis; Vitamin D; Vitamin D deficiency

Indexed keywords

CALCITRIOL; VITAMIN D; VITAMIN D DERIVATIVE; COLECALCIFEROL;

ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; BLOOD; COMPLICATION; NEOPLASMS; VITAMIN D DEFICIENCY;

CALCITRIOL; CHOLECALCIFEROL; HUMANS; NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84938334005     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(15)30043-1     Document Type: Article

References (139)

1. Garland CF, Garland FC Do sunlight and vitamin D reduce the likelihood of colon cancer? [J]. Int J Epidemiol 1980, 9(3):227-231.
2. Krishnan AV, Trump DL, Johnson CS, et al. The role of vitamin D in cancer prevention and treatment [J]. Endocrin Metab Clin 2010, 39(2):401-418.
3. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression [J]. Nat Rev Cancer 2014, 14(5):342-357.
4. Feldman D, Pike JW, Adams JS Vitamin D [M] 2011, Elsevier Academic Press. 3rd Ed.
5. Moukayed M, Grant WB Molecular link between vitamin D and cancer prevention [J]. Nutrients 2013, 5(10):3993-4021.
6. Deeb KK, Trump DL, Johnson CS Vitamin D signalling pathways in cancer: potential for anticancer therapeutics [J]. Nat Rev Cancer 2007, 7(9):684-700.
7. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an endocrine society scientific statement [J]. Endocr Rev 2012, 33(3):456-492.
8. Pereira F, Larriba MJ, Muñoz A Vitamin D and colon cancer [J]. Endocr-Relat Cancer 2012, 19(3):R51-R71.
9. Wranicz J, Szostak-Wegierek D Health outcomes of vitamin D. Part II. Role in prevention of diseases [J]. Rocz Panstw Zakl Hig 2014, 65(4):273-279.
10. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: What clinicians need to know [J]. J Clin Endocr Met 2011, 96(1):53-58.
11. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline [J]. J Clin Endocr Met 2011, 96(7):1911-1930.
12. Hobaus J, Thiem UM, Hummel D, et al. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis [J]. Anti-Cancer Agent Me 2013, 13(1):20-35.
13. Holick MF Vitamin D and bone health [J]. J Nutr 1996, 126(4 Suppl):1159S-1164S.
14. Fleet JC, DeSmet M, Johnson R, et al. Vitamin D and cancer: a review of molecular mechanisms [J]. Biochem J 2012, 441(1):61-76.
15. Huhtakangas JA, Olivera CJ, Bishop JE, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-Vitamin D3 in vivo and in vitro [J]. Mol Endocrinol 2004, 18(11):2660-2671.
16. 3 membrane binding protein (1, 25D3-MARRS) and phosphate uptake in intestinal cells [J]. P Natl A Sci USA 2004, 101(19):7392-7397.
17. Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery [J]. Mol Endocrinol 2001, 15(8):1370-1380.
18. Salehi-Tabar R, Nguyen-Yamamoto L, Tavera-Mendoza LE, et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network [J]. P Natl A Sci USA 2012, 109(46):18827-18832.
19. Meyer MB, Goetsch PD, Pike JW VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression [J]. Mol Endocrinol 2012, 26(1):37-51.
20. 1 arrest [J]. Prostate 2011, 71(1):98-110.
21. Li P, Li C, Zhao X, et al. P27(Kip1) stabilization and G(1) arrest by 1, 25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase [J]. J Biol Chem 2004, 279(24):25260-25267.
22. Akutsu N, Lin R, Bastien Y, et al. Regulation of gene expression by 1alpha, 25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells [J]. Mol Endocrinol 2001, 15(7):1127-1139.
23. Bao BY, Hu YC, Ting HJ, et al. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells [J]. Oncogene 2004, 23(19):3350-3360.
24. Chiang KC, Yeh CN, Chen SC, et al. MART-10, a new generation of vitamin D analog, Is more potent than 1alpha, 25-Dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells [J]. Evid-Based Compl Alt 2012, 2012:310872.
25. Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy [J]. Cancer Res 2000, 60(8):2304-2312.
26. Liu CY, Flesken-Nikitin A, Li S, et al. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development [J]. Genes Dev 1996, 10(14):1835-1843.
27. Pendas-Franco N, Aguilera O, Pereira F, et al. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes [J]. Anticancer Res 2008, 28(5A):2613-2623.
28. Gocek E, Studzinski GP Vitamin D and differentiation in cancer [J]. Crit Rev Cl Lab Sc 2009, 46(4):190-209.
29. Villaggio B, Soldano S, Cutolo M 1, 25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages [J]. Clin Exp Rheumatol 2012, 30(6):934-938.
30. Kaler P, Augenlicht L, Klampfer L Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3 [J]. Oncogene 2009, 28(44):3892-3902.
31. Kovalenko PL, Zhang Z, Cui M, et al. 1, 25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1 [J]. BMC Genomics 2010, 11:26.
32. Bao BY, Yao J, Lee YF 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis [J]. Carcinogenesis 2006, 27(9):1883-1893.
33. Tse AK, Zhu GY, Wan CK, et al. 1alpha, 25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells [J]. Mol immunol 2010, 47(9):1728-1738.
34. Dormoy V, Beraud C, Lindner V, et al. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma [J]. Carcinogenesis 2012, 33(11):2084-2093.
35. Krishnan AV, Shinghal R, Raghavachari N, et al. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays [J]. Prostate 2004, 59(3):243-251.
36. Figueroa JA, De Raad S, Tadlock L, et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer [J]. J Urology 1998, 159(4):1379-1383.
37. Kriebitzsch C, Verlinden L, Eelen G, et al. The impact of 1, 25(OH)2D3 and its structural analogs on gene expression in cancer cells-a microarray approach [J]. Anticancer Res 2009, 29(9):3471-3483.
38. Lee HJ, Liu H, Goodman C, et al. Gene expression profiling changes induced by a novel gemini vitamin D derivative during the progression of breast cancer [J]. Biochem Pharmacol 2006, 72(3):332-343.
39. Swami S, Raghavachari N, Muller UR, et al. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray [J]. Breast Cancer Res Tr 2003, 80(1):49-62.
40. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling [J]. J Cell Biol 2001, 154(2):369-387.
41. Beildeck ME, Islam M, Shah S, et al. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines [J]. PLoS ONE 2009, 4(11):e7872.
42. 1 accumulation in C4-2 prostate cancer cells [J]. Endocrinology 2009, 150(5):2046-2054.
43. Rawson JB, Sun Z, Dicks E, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients [J]. Nutr Cancer 2012, 64(7):919-928.
44. Aguilera O, Pena C, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells [J]. Carcinogenesis 2007, 28(9):1877-1884.
45. Ben-Shoshan M, Amir S, Dang DT, et al. 1alpha, 25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells [J]. Mol Cancer Ther 2007, 6(4):1433-1439.
46. Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo [J]. Cancer Res 2009, 69(3):967-975.
47. Morelli S, Buitrago C, Boland R, et al. The stimulation of MAP kinase by 1, 25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium [J]. Mol Cell Endocrinol 2001, 173(1-2):41-52.
48. Goeman F, De Nicola F, De Meo PD, et al. VDR primary targets by genome-wide transcriptional profiling [J]. J Steroid Biochem 2014, 143:348-356.
49. Beaudin SG, Robilotto S, Welsh J Comparative regulation of gene expression by 1, 25-dihydroxyvitamin D3 in cells derived from normal mammary tissue and breast cancer [J]. J Steroid Biochem 2015, 148:96-102.
50. Zhang Z, Zhang H, Hu Z, et al. Synergy of 1, 25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells [J]. Oncol Lett 2014, 8(3):1348-1354.
51. Linnewiel-Hermoni K, Khanin M, Danilenko M, et al. The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity [J]. Arch Biochem Biophys 2015, 572:28-35.
52. Meeker S, Seamons A, Paik J, et al. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer [J]. Cancer Res 2014, 74(16):4398-4408.
53. Rebel H, der Spek CD, Salvatori D, et al. UV exposure inhibits intestinal tumor growth and progression to malignancy in intestine-specific Apc mutant mice kept on low vitamin D diet [J]. Int J Cancer 2015, 136(2):271-277.
54. Kasiappan R, Sun Y, Lungchukiet P, et al. Vitamin D suppresses leptin stimulation of cancer growth through microRNA [J]. Cancer Res 2014, 74(21):6194-6204.
55. Lang K, Ratke J Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration [J]. Cell Commun Signal 2009, 7:27.
56. Skaaby T, Husemoen LL, Thyssen JP, et al. Filaggrin loss-of-function mutations and incident cancer: a population-based study [J]. Brit J Dermatol 2014, 171(6):1407-1414.
57. Irvine AD, McLean WH, Leung DY Filaggrin mutations associated with skin and allergic diseases [J]. New Engl J Med 2011, 365(14):1315-1327.
58. Thyssen JP, Thuesen B, Huth C, et al. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations [J]. J Allergy Clin Immun 2012, 130(5):1204-1207.e1202.
59. Moy KA, Mondul AM, Zhang H, et al. Genome-wide association study of circulating vitamin D-binding protein [J]. Am J Clin Nutr 2014, 99(6):1424-1431.
60. Ashktorab H, Nguza B, Fatemi M, et al. Case-control study of vitamin D, dickkopf homolog 1 (DKK1) gene methylation, VDR gene polymorphism and the risk of colon adenoma in African Americans [J]. PLoS ONE 2011, 6(10):e25314.
61. Atoum MF, Tchoporyan MN Association between circulating vitamin D, the Taq1 vitamin D receptor gene polymorphism and colorectal cancer risk among Jordanians [J]. Asian Pac J Cancer Prev 2014, 15(17):7337-7341.
62. Kostner K, Denzer N, Muller CSL, et al. The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature [J]. Anticancer Res 2009, 29(9):3511-3536.
63. Serrano D, Gnagnarella P, Raimondi S, et al. Meta-analysis on vitamin D receptor and cancer risk: focus on the role of TaqI, ApaI, and Cdx2 polymorphisms [J]. Eur J Cancer Prev 2015.
64. Gnagnarella P, Pasquali E, Serrano D, et al. Vitamin D receptor polymorphism FokI and cancer risk: a comprehensive meta-analysis [J]. Carcinogenesis 2014, 35(9):1913-1919.
65. Raimondi S, Pasquali E, Gnagnarella P, et al. BsmI polymorphism of vitamin D receptor gene and cancer risk: A comprehensive meta-analysis [J]. Mut Res-Fund Mol M 2014, 769:17-34.
66. Anderson LN, Cotterchio M, Knight JA, et al. Genetic variants in Vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada [J]. PLoS ONE 2013, 8(6):e66768.
67. Kim Y, Je Y Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis [J]. Br J Cancer 2014, 110(11):2772-2784.
68. Wang J, Eliassen AH, Spiegelman D, et al. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II [J]. Cancer Cause Contr 2014, 25(7):819-827.
69. Li M, Chen P, Li J, et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis [J]. J Clin Endocr Met 2014, 99(7):2327-2336.
70. Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the prostate, lung, colorectal and ovarian cancer screening trial [J]. Int J Cancer 2015, 136(6):E654-E664.
71. Anic GM, Weinstein SJ, Mondul AM, et al. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer [J]. PLoS One 2014, 9(7):e102966.
72. Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer [J]. J Clin Oncol 2014, 32(23):2430-2439.
73. Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk: results from the selenium and Vitamin E cancer prevention trial [J]. Cancer Epidem Biomar 2014, 23(8):1494-1504.
74. Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial [J]. Cancer Epidem Biomar 2014, 23(8):1484-1493.
75. Cheng TY, Goodman GE, Thornquist MD, et al. Estimated intake of vitamin D and its interaction with vitamin A on lung cancer risk among smokers [J]. Int J Cancer 2014, 135(9):2135-2145.
76. Ng K, Scott JB, Drake BF, et al. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial [J]. Am J Clin Nutr 2014, 99(3):587-598.
77. Chandler PD, Scott JB, Drake BF, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial [J]. Cancer Prev Res 2014, 7(2):218-225.
78. Fabian C. Modulation of breast cacner risk biomarkers by high dose vitamin D [J]. , 2010. http://ClinicalTrials.gov.
79. University of Illinois at Chicago. Efficacy of vitamin D in colorectal cancer chemoprevention [EB/OL]. 2012: . http://ClinicalTrials.gov.
80. Murphy AB, Nyame Y, Martin IK, et al. Vitamin D deficiency predicts prostate biopsy outcomes [J]. Clin Cancer Res 2014, 20(9):2289-2299.
81. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study [J]. J Natl Cancer I 2012, 104(9):690-699.
82. Gambichler T, Bindsteiner M, Hoxtermann S, et al. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma [J]. Brit J Dermatol 2013, 168(3):625-628.
83. Bade B, Zdebik A, Wagenpfeil S, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis [J]. PLoS ONE 2014, 9(12):e112863.
84. Wesa KM, Segal NH, Cronin AM, et al. Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis [J]. Nutr Cancer 2015, 67(3):424-430.
85. Lee HJ, Muindi JR, Tan W, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia [J]. Cancer 2014, 120(4):521-529.
86. Peiris AN, Bailey BA, Manning T Relationship of vitamin D monitoring and status to bladder cancer survival in veterans [J]. South Med J 2013, 106(2):126-130.
87. Houghton LA, Vieth R The case against ergocalciferol (vitamin D2) as a vitamin supplement [J]. Am J Clin Nutr 2006, 84(4):694-697.
88. Leyssens C, Verlinden L, Verstuyf A The future of vitamin D analogs [J]. Front Physiol 2014, 5:122.
89. Mazzaferro S, Goldsmith D, Larsson TE, et al. Vitamin D metabolites and/or analogs: which D for which patient? [J]. Curr Vasc Pharmacol 2014, 12(2):339-349.
90. Cheung FS, Lovicu FJ, Reichardt JK Current progress in using vitamin D and its analogs for cancer prevention and treatment [J]. Expert Rev Anticanc 2012, 12(6):811-837.
91. Brown AJ, Slatopolsky E Vitamin D analogs: therapeutic applications and mechanisms for selectivity [J]. Mol Aspects Med 2008, 29(6):433-452.
92. Sintov AC, Yarmolinsky L, Dahan A, et al. Pharmacological effects of vitamin D and its analogs: recent developments [J]. Drug Discov Today 2014, 19(11):1769-1774.
93. Hylander E, Jarnum S 1α-Hydroxyvitamin D3 in Intestinal Calcium Malabsorption [J]. Scand J Gastroentero 1980, 15(4):443-448.
94. Hellstrom E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG) [J]. Eur J Haematol 1990, 45(5):255-261.
95. Motomura S, Kanamori H, Maruta A, et al. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes [J]. Am J Hematol 1991, 38(1):67-68.
96. Petrini M, Caracciolo F, Corini M, et al. Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study [J]. Haematologica 1991, 76(3):200-203.
97. Petrini M, Caracciolo F, Carulli G, et al. Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia [J]. Acta Haematol-Basel 1993, 89(4):184-188.
98. Trouillas P, Honnorat J, Bret P, et al. Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol [J]. J Neuro-Oncol 2001, 51(1):57-66.
99. Obara W, Mizutani Y, Oyama C, et al. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma [J]. Int J Urol 2008, 15(9):794-799.
100. Binderup L, Bramm E Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo [J]. Biochem Pharmacol 1988, 37(5):889-895.
101. Bower M, Colston KW, Stein RC, et al. Topical calcipotriol treatment in advanced breast cancer [J]. Lancet 1991, 337(8743):701-702.
102. O'Brien ME, Talbot D, Maclennan K, et al. Inefficacy of calcipotriol in skin metastases from breast cancer [J]. Lancet 1993, 342(8877):994.
103. Liu G, Oettel K, Ripple G, et al. Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer [J]. Clin Cancer Res 2002, 8(9):2820-2827.
104. Liu G, Wilding G, Staab MJ, et al. Phase II study of 1α-hydroxyvitamin D2 in the treatment of advanced androgen-independent prostate cancer [J]. Clin Cancer Res 2003, 9(11):4077-4083.
105. Attia S, Eickhoff J, Wilding G, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer [J]. Clin Cancer Res 2008, 14(8):2437-2443.
106. Gee J, Bailey H, Kim K, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin [J]. Prostate 2013, 73(9):970-978.
107. Petrich A, Kahl B, Bailey H, et al. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome [J]. Leukemia Lymphoma 2008, 49(1):57-61.
108. M. D. Anderson Cancer Center. Doxercalciferol in recurrent pediatric solid tumors [EB/OL]. 2007: . http://ClinicalTrials.gov.
109. Zhou JY, Norman AW, Lubbert M, et al. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization [J]. Blood 1989, 74(1):82-93.
110. Wieder R, Novick SC, Hollis BW, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies [J]. Invest New Drug 2003, 21(4):445-452.
111. Jain RK, Trump DL, Egorin MJ, et al. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors [J]. Invest New Drug 2011, 29(6):1420-1425.
112. Verlinden L, Verstuyf A, Van Camp M, et al. Two novel 14-Epi-analogues of 1, 25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo [J]. Cancer Res 2000, 60(10):2673-2679.
113. Medioni J, Deplanque G, Ferrero JM, et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients [J]. Clin Cancer Res 2014, 20(17):4471-4477.
114. Hybrigenics launches phase II clinical study of inecalcitol in chronic myeloid leukemia [C]. LSP 2015.
115. Chen TC, Schwartz GG, Burnstein KL, et al. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer [J]. Clin Cancer Res 2000, 6(3):901-908.
116. Schwartz GG, Hall MC, Stindt D, et al. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer [J]. Clin Cancer Res 2005, 11(24 Pt 1):8680-8685.
117. Lawrence JA, Akman SA, Melin SA, et al. Oral paricalcitol (19-nor-1, 25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial [J]. Cancer Biol Ther 2013, 14(6):476-480.
118. Colston KW, Mackay AG, James SY, et al. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro [J]. Biochem Pharmacol 1992, 44(12):2273-2280.
119. Gulliford T, English J, Colston KW, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer [J]. Brit J Cancer 1998, 78(1):6-13.
120. Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer [J]. Brit J Cancer 2002, 86(5):680-685.
121. Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma [J]. Brit J Cancer 2003, 89(2):252-257.
122. LEO Pharma Seocalcitol versus placebo in advanced hepatocellular carcinoma [J]. Clinical Trials. Gov 2007.
123. LEO Pharma Seocalcitol versus placebo in the adjuvant treatment of hepatocellular carcinoma [J]. Clinical Trials. Gov 2007.
124. Brard L, Lange TS, Robison K, et al. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines [J]. Gynecol Oncol 2011, 123(2):370-378.
125. Chen B, Kawai M, Wu-Wong JR Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects [J]. Bioorg Med Chem Lett 2013, 23(21):5949-5952.
126. Ma Y, Yu WD, Hidalgo AA, et al. Inecalcitol, an analog of 1, 25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system [J]. Cell Cycle 2013, 12(5):743-752.
127. Chen J, Wang J, Kim TK, et al. Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity [J]. Anticancer Res 2014, 34(5):2153-2163.
128. Chiang KC, Yeh CN, Hsu JT, et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells [J]. Cancer Lett 2014, 354(2):235-244.
129. Deluca HF The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 [J]. Bonekey Rep 2014, 3:514.
130. Kudo T, Ishizawa M, Maekawa K, et al. Combination of triple bond and adamantane ring on the vitamin D side chain produced partial agonists for vitamin D receptor [J]. J Med Chem 2014, 57(10):4073-4087.
131. Slominski AT, Zmijewski MA, Semak I, et al. Cytochromes p450 and skin cancer: role of local endocrine pathways [J]. Anticancer Agents Med Chem 2014, 14(1):77-96.
132. Fred Hutchison Cancer Research Center. Vitamin D, diet, and activity study (ViDA) [EB/OL]. 2010: , NCT01240213. http://ClinicalTrials.gov.
133. Shanghai Jiao Tong University School of Medicine. Study of folic acid, calcium and Vitamin D in preventing colorectal polyps and colorectal cancer [EB/OL]. 2014: , NCT0206688. http://ClinicalTrials.gov.
134. Brigham and Women's Hospital. Vitamin and Omega-3 Trial (VITAL) [EB/OL]. 2010: , NCT01169259. http://ClinicalTrials.gov.
135. University of Eastern Finland. Finnish Vitamin D Trial (FIND) [EB/OL]. 2011: , NCT01463813. http://ClinicalTrials.gov.
136. Emory University. Calcium/Vitamin D, biomarkers & colon polyp prevention (PPS4B) [EB/OL]. 2006: , NCT00399607. http://ClinicalTrials.gov.
137. Southwest Oncology Group. S0812 high dose cholecalciferol in premenopausal women at high-risk for breast cancer [EB/OL]. 2010: , NCT01097278. http://ClinicalTrials.gov.
138. Johns Hopkins University. Study of high-dose oral Vitamin D for the prevention of liver cancer [EB/OL]. 2013: , NCT01956864. http://ClinicalTrials.gov.
139. Creighton University. Clinical trial of Vitamin D3 to reduce cancer risk in postmenopausal women (CAPS) [EB/OL]. 2010: , NCT01052051. http://ClinicalTrials.gov.